NASDAQ : CCCC
C4 Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.3 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 405.98M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 414.59M |
| Enterprise Value | 171.00M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 123.03M |
| Shares Outstanding | 123.03M |
| Shares Change (YoY) | +58.30% |
| Shares Change (QoQ) | +3.67% |
| Owned by Insiders (%) | 1.04% |
| Owned by Institutions (%) | 86.75% |
| Float | 94.50M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.83 |
| Forward PS | 17.63 |
| PB Ratio | 1.68 |
| P/TBV Ratio | 1.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.88 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.45 |
| Quick Ratio | 5.29 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -48.14% |
| Return on Assets (ROA) | -19.25% |
| Return on Invested Capital (ROIC) | -23.34% |
| Return on Capital Employed (ROCE) | -32.47% |
| Weighted Average Cost of Capital (WACC) | 19.01% |
| Revenue Per Employee | $336,913 |
| Profits Per Employee | -$975,154 |
| Employee Count | 104 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 121,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.16 |
| 52-Week Price Change | +34.26% |
| 50-Day Moving Average | 3.32 |
| 200-Day Moving Average | 3.21 |
| Relative Strength Index (RSI) | 56.98 |
| Average Volume (20 Days) | 2,857,139 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 42.72M |
| Short Previous Month | 40.40M |
| Short % of Shares Out | 34.73% |
| Short % of Float | 45.21% |
| Short Ratio (days to cover) | 17.84 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 35.04M |
| Gross Profit | 30.25M |
| Operating Income | -101.03M |
| Pretax Income | -101.30M |
| Net Income | -101.42M |
| EBITDA | -99.45M |
| EBIT | -101.03M |
| Loss Per Share | -$0.91 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 253.66M |
| Total Debt | 56.86M |
| Net Cash | 243.59M |
| Net Cash Per Share | $1.98 |
| Equity (Book Value) | 247.27M |
| Book Value Per Share | 2.01 |
| Working Capital | 214.66M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -84.87M |
| Capital Expenditures | -523,000 |
| Depreciation & Amortization | 1.58M |
| Net Borrowing | n/a |
| Free Cash Flow | -85.39M |
| FCF Per Share | -$0.69 |
Margins
| Measure | Value |
|---|
| Gross Margin | 86.34% |
| Operating Margin | -288.34% |
| Pretax Margin | -289.09% |
| Profit Margin | -289.44% |
| EBITDA Margin | -283.82% |
| EBIT Margin | -288.34% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -58.30% |
| Shareholder Yield | -58.30% |
| Earnings Yield | -26.96% |
| FCF Yield | -20.60% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $12.63 |
| Price Target Difference | 274.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | -16.68% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.87 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |